Abstract Number: 2759 • 2013 ACR/ARHP Annual Meeting
Can RA Registries Provide Contextual Safety Data For Modern RCTs?
Background/Purpose: For ethical reasons, modern phase-III RCTs in rheumatoid arthritis (RA) have limited placebo exposure time, resulting in uncertainties when interpreting low frequency adverse events…Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…Abstract Number: 2761 • 2013 ACR/ARHP Annual Meeting
Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Background/Purpose: Several newer biologics have been approved for treatment of rheumatoid arthritis (RA) in the United States. However, their comparative risks of herpes zoster infection…Abstract Number: 2762 • 2013 ACR/ARHP Annual Meeting
Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory conditions that are associated with increased risk of insulin resistance and cardiovascular disease…Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting
Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…Abstract Number: 2764 • 2013 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Tocilizumab More Effective Than Tocilizumab in Rapid Radiographic Progression Patients With Rheumatoid Arthritis. A Randomized, Open Label, x Ray Reader Blinded Study
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…Abstract Number: 2765 • 2013 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis
Background/Purpose: HMG -CoA reductase inhibitors (statins) are standard treatment for hyperlipidemia. In addition to lipid lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of…Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting
Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…Abstract Number: 2769 • 2013 ACR/ARHP Annual Meeting
Clinical Remission After 52 Weeks Of Treatment Is a Predictor Of Adalimumab-Free Disease Control In Patients With Early Rheumatoid Arthritis: Hopeful 2 Study
Background/Purpose: Although it is possible to achieve remission or low disease activity (LDA) with the combination of methotrexate (MTX) and biologics for many patients with…Abstract Number: 2770 • 2013 ACR/ARHP Annual Meeting
Complex Functional Effects Within The HLA Contribute To Sjögren’s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common, heterogeneous exocrinopathy. Etiology involves complex environmental, genetic and genomic influences driving innate and adaptive autoimmune responses. This…Abstract Number: 2771 • 2013 ACR/ARHP Annual Meeting
The NKp30/B7H6 Axis Contributes To Pathogenesis In Primary Sjögren’s Syndrome
Background/Purpose: NK cells are an important subset of cells involved in innate immunity. Their possible role has never been studies in pSS pathogeny. We aimed…Abstract Number: 2772 • 2013 ACR/ARHP Annual Meeting
Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching
Background/Purpose: Sjögren’s syndrome (SS) is a common, progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of the European population.…Abstract Number: 2773 • 2013 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Patterns In naïve CD4+ T Cells From Patients With Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (PSS) is a systemic autoimmune disease characterized by inflammation of the lacrimal and salivary glands and dryness of the eyes and mouth.…
ACR Meeting Abstracts